NA
NTLA icon

NewEdge Advisors’s Intellia Therapeutics NTLA Stock Holding History

NewEdge Advisors’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.08K Sell
300
-1,100
-79% -$15.4K ﹤0.01% 3717
2026
Q1 		$17.9K Sell
1,400
-200
-13% -$2.55K ﹤0.01% 3226
2025
Q4 		$14.4K Sell
1,600
-685
-30% -$9.43K ﹤0.01% 3355
2025
Q3 		$39.5K Hold
2,285
– – ﹤0.01% 2899
2025
Q2 		$21.4K Buy
2,285
+800
+54% +$6.57K ﹤0.01% 2935
2025
Q1 		$10.6K Buy
+1,485
New +$15K ﹤0.01% 3082
2024
Q4 		– Sell
-300
Closed -$6.17K – 3981
2024
Q3 		$6.17K Buy
+300
New +$6.92K ﹤0.01% 3090
2024
Q2 		– Sell
-40
Closed -$1.1K – 3943
2024
Q1 		$1.1K Buy
+40
New +$1.11K ﹤0.01% 3480
2023
Q4 		– Sell
-3
Closed -$95 – 3838
2023
Q3 		$95 Sell
3
-333
-99% -$12.9K ﹤0.01% 3368
2023
Q2 		$13.7K Sell
336
-183
-35% -$7.42K ﹤0.01% 2503
2023
Q1 		$19.3K Sell
519
-725
-58% -$28.4K ﹤0.01% 2354
2022
Q4 		$28.7K Buy
+1,244
New +$59.1K ﹤0.01% 1984

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

NewEdge Advisors's NTLA Position: Q2 2026 in Review

NewEdge Advisors reduced its Intellia Therapeutics (NTLA) stake by 79% in Q2 2026, selling an estimated $15.4K and leaving 300 shares worth $5.08K. The position accounts for ﹤0.01% of the portfolio, ranked #3717.

NewEdge Advisors first reported a position in NTLA in Q4 2022 and has held it in 12 quarters since. The position peaked at $39.5K in Q3 2025. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • NewEdge Advisors held 300 shares of Intellia Therapeutics worth $5.08K as of Q2 2026.
  • NewEdge Advisors sold 1,100 Intellia Therapeutics shares in Q2 2026, an estimated $15.4K.
  • Intellia Therapeutics made up ﹤0.01% of NewEdge Advisors's portfolio in Q2 2026, its #3717 holding.
  • NewEdge Advisors first reported a position in Intellia Therapeutics in Q4 2022 and has held it in 12 quarters since.
  • NewEdge Advisors's Intellia Therapeutics position peaked at $39.5K in Q3 2025.
  • 328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on NewEdge Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.